NEW LIMITATION CHANGE

TO
Approved for public release, distribution unlimited

FROM
Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; May 2000. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD 21702-5012

AUTHORITY
USAMRMC ltr, 8 Jan 2003
Award Number: DAMD17-99-1-9373

TITLE: Total Synthesis of Eleutherobin and Analogs and Study of Anti-Cancer Mechanism

PRINCIPAL INVESTIGATOR: Qiang Tan, Ph.D.
Samuel Danishefsky, Ph.D.

CONTRACTING ORGANIZATION: Sloan Kettering Institute for Cancer Research
New York, New York 10021

REPORT DATE: May 2000

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, May 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9373
Organization: Sloan Kettering Institute
Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure, or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure, or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

[Signature]

[Date: 12/10/98]
A modified eleutherobin synthesis is being studied. Compared to the initial synthesis, the new synthesis is designed to improve the stereoselectivity of key steps and shorten the sequence.
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signature  April 25, 2000

Date
# Table of Contents

Cover..................................................................................................................

SF 298..................................................................................................................

Foreword............................................................................................................

Table of Contents...............................................................................................5

Introduction..........................................................................................................6

Body.......................................................................................................................7

Key Research Accomplishments........................................................................9

Reportable Outcomes.........................................................................................10

Conclusions.........................................................................................................11

References..........................................................................................................12

Appendices.........................................................................................................N/A
Introduction:

Eleutherobin is a marine natural product discovered in 1994. It serves as one of the most potent anti-cancer agents mimicking Taxol. The proposed research is focused on improving the total synthesis of eleutherobin, and based on that developing eleutherobin analogs for biological studies.
The above Scheme 1 outlines the initial synthesis developed in this lab (1). It features an addition of 2-bromo-5-lithiofuran to aldehyde 3 to give the key intermediate 4 (57% yield). The C8 epimer is also isolated as a monor product (ca. 7:5 diastereomeric ratio). Although the epimer can be recycled, the efficiency of the synthesis certainly has a room for improvement.

Scheme 2 shows the new retrosynthetic plan in which the key intermediate 6 will be obtained through the reduction of ketone 8. Various reducing agents can be screened to optimize the stereoselectivity. Ketone 8 can be synthesized from 9 through a Claisen rearrangement. Prior to that, the C1 side chain can be installed by alkylation utilizing the enone function of (-)-Carvone 10.
Scheme 3 shows the current work. The yields are approximate since they are still under optimization. (-)-Carvone 10 was selectively hydrogenated at the terminal double bond using Wilkinson's catalyst without affecting the enone function. As a modification to the reported procedure (2), it was discovered that the application of a moderate high pressure (1600 psi) is necessary for a efficient hydrogenation. The dihydrocarvone 11 obtained was then converted to the thermodynamically more favored TMS ether diene 12. The published procedure (3) uses a catalytical amount of FeCl₃, but under our hands a 3.0 eq. of FeCl₃ has to be applied to obtain a satisfactory conversion. Lewis acid induced alkylation leads to dimethyl acetal 13 (4). The stereoselective reduction of the ketone is achieved with L-Selectride (4) to give the alcohol 14, which was coupled with bromo-furanyl acid 15 to give the ester 16. Treatment of Tebbe reagent gave 17 which sets up the stage for a Claisen rearrangement to give 8. Currently, various reducing agents are being tested to reduce C8 ketone to the desired stereoisomer. Work is also being carried out to elongate the C1 side chain by one carbon. Also under study is the idea of installing a two-carbon side chain at C1 in the beginning of the synthesis, which will further shorten the sequence.
Key Research Accomplishments:

Promising results have been obtained on an improved eleutherobin synthesis. Several key steps, including Claisen rearrangement on an advanced intermediate, have been worked out.
Reportable Outcomes:

N/A (early stage of the research).
Conclusions:

An improved eleutherobin synthesis is under development and shows promising results.
Reference:


MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to the enclosed. Request the limited distribution statement for the enclosed be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

Phyllis M. Rinehart
Deputy Chief of Staff for Information Management
<table>
<thead>
<tr>
<th>ADB265840</th>
<th>ADB266633</th>
<th>ADB282069</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADB279138</td>
<td>ADB251763</td>
<td>ADB265386</td>
</tr>
<tr>
<td>ADB264578</td>
<td>ADB281601</td>
<td>ADB282057</td>
</tr>
<tr>
<td>ADB281679</td>
<td>ADB258874</td>
<td>ADB258251</td>
</tr>
<tr>
<td>ADB281645</td>
<td>ADB281773</td>
<td>ADB264541</td>
</tr>
<tr>
<td>ADB261128</td>
<td>ADB281660</td>
<td>ADB241630</td>
</tr>
<tr>
<td>ADB261339</td>
<td>ADB259064</td>
<td>ADB281924</td>
</tr>
<tr>
<td>ADB273096</td>
<td>ADB266141</td>
<td>ADB281663</td>
</tr>
<tr>
<td>ADB281681</td>
<td>ADB281664</td>
<td>ADB281659</td>
</tr>
<tr>
<td>ADB259637</td>
<td>ADB258830</td>
<td></td>
</tr>
<tr>
<td>ADB256645</td>
<td>ADB266029</td>
<td></td>
</tr>
<tr>
<td>ADB262441</td>
<td>ADB281668</td>
<td></td>
</tr>
<tr>
<td>ADB281674</td>
<td>ADB259834</td>
<td></td>
</tr>
<tr>
<td>ADB281771</td>
<td>ADB266075</td>
<td></td>
</tr>
<tr>
<td>ADB281612</td>
<td>ADB281661</td>
<td></td>
</tr>
</tbody>
</table>